1990—2021年中国0~19岁儿童和青少年白血病疾病负担分析

doi:10.11904/j.issn.1002-3070.2025.02.001

实用肿瘤学杂志 ›› 2025, Vol. 39 ›› Issue (2): 73-79.doi: 10.11904/j.issn.1002-3070.2025.02.001

• 癌情监测 • 下一篇

1990—2021年中国0~19岁儿童和青少年白血病疾病负担分析

王心雨¹, 蔡思雨²

1.国家儿童医学中心首都医科大学附属北京儿童医院大数据中心(北京 100045);
2.国家儿童医学中心首都医科大学附属北京儿童医院临床流行病与循证医学中心

收稿日期:2024-11-20 修回日期:2025-02-03 出版日期:2025-04-28 发布日期:2025-05-06
通讯作者: 王心雨,E-mail:wangxy_bch@163.com
作者简介:王心雨,女,(1989—),博士,助理研究员,从事大数据挖掘和儿童慢性病管理研究。
基金资助:
2022年度慢性病防治与健康教育科研项目(编号:BJMB0012022028010);2023年拾玉舒缓安宁科研基金·儿童专项(编号:2023YB05)

Analysis of leukemia disease burden in children and adolescents aged 0-19 years in China from 1990 to 2021

WANG Xinyu¹, CAI Siyu²

1. Big Data Center,Beijing Children's Hospital,Capital Medical University,National Center for Children's Health,Beijing 100045, China;
2. Center for Clinical Epidemiology and Evidence-based Medicine,Beijing Children's Hospital,Capital Medical University,National Center for Children's Health

Received:2024-11-20 Revised:2025-02-03 Online:2025-04-28 Published:2025-05-06

摘要/Abstract

摘要： 目的分析1990—2021年中国0~19岁儿童和青少年白血病的疾病负担趋势,为该群体的疾病预防控制策略提供科学依据。方法利用2021年全球疾病负担数据库(GBD 2021),分析中国(不含中国台湾地区)儿童和青少年白血病的疾病负担,包括发病率、患病率、死亡率和伤残调整寿命年(disability-adjusted life year,DALY)。DALY由早死损失寿命年(years of life lost,YLL)和伤残损失寿命年(years lived with disability,YLD)两部分组成。采用平均年度变化百分比(average annual percentage change,AAPC)综合评价1990—2021年中国儿童白血病疾病负担各指标的变化趋势。结果 2021年中国0~19岁人群的年龄标准化发病率、患病率、死亡率和DALY率分别为7.33/10万、51.46/10万、1.72/10万和142.14/10万;其中,男性的年龄标准化发病率、患病率、死亡率和DALY率高于女性;0-岁群体的各项发病率、患病率、死亡率和DALY率均高于其他年龄组;急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)的年龄标准化发病率、患病率、死亡率和DALY率均高于其他白血病分型。1990—2021年,0~19岁人群的白血病年龄标准化发病率未呈现明显增长或下降趋势(AAPC=-0.32%,95% CI:-0.66%~0.02%);年龄标准化患病率呈现显著上升趋势(AAPC=3.05%,95% CI:2.68%~3.42%);而年龄标准化死亡率和DALY率呈下降趋势(AAPC=-4.27%,95% CI:-4.53%~-4.01%;AAPC=-4.30%,95% CI:-4.56%~-4.05%)。结论 1990—2021年,中国0~19岁儿童和青少年白血病的患病负担在增加,死亡负担在减少,总的DALY负担在下降。该群体的白血病负担在不同年龄、性别和分型存在较大差异。

关键词: 白血病, 疾病负担, 儿童, 青少年

Abstract: Objective The Objective of this study was to analyze the disease burden trend of leukemia in children and adolescents aged 0-19 years in China from 1990 to 2021,and to provide a scientific evidence for the disease prevention and control strategy of this population. Methods The disease burden of leukemia in children and adolescents in China(excluding Taiwan)was analyzed using the Global Burden of Disease Database 2021(GBD 2021),including incidence,prevalence,mortality,and disability-adjusted life year(DALY).DALY consisted of two parts:years of life lost(YLL)and years lived with disability(YLD).The average annual percentage change(AAPC)was used to comprehensively evaluate the changing trends of various indicators from the disease burden of childhood leukemia in China from 1990 to 2021. Results In 2021,the age-standardized incidence,prevalence,mortality and DALY rates of the 0-19 years old population in China were 7.33/100,000,51.46/100,000,1.72/100,000,and 142.14/100,000,respectively.Among them,the age-standardized incidence,prevalence,mortality and DALY rates of males were higher than those of females.The incidence,prevalence,mortality and DALY rates of the 0- years old group were higher than those of other age groups.The age-standardized incidence,prevalence,mortality and DALY rates of acute lymphoblastic leukemia(ALL)were higher than those of other leukemia subtypes.From 1990 to 2021,the leukemia age-standardized incidence in the population aged 0 to 19 years did show a significant increase or decrease(AAPC=-0.32%,95% CI:-0.66%-0.02%);the age-standardized prevalence showed a significant increase(AAPC=3.05%,95% CI:2.68%-3.42%).While age-standardized mortality and DALY rates showed a downward trend(AAPC=-4.27%,95% CI:-4.53%-4.01%;AAPC=-4.3%,95% CI:-4.56%-4.05%). Conclusion From 1990 to 2021,the disease burden of leukemia in children and adolescents aged 0 to 19 years in China is increasing,the burden of death is decreasing,and the total DALY is decreasing.The burden of leukemia in this group varies greatly among different ages,genders,and leukemia subtypes.

Key words: Leukemia, Burden of diseases, Children, Adolescents

中图分类号:

王心雨, 蔡思雨. 1990—2021年中国0~19岁儿童和青少年白血病疾病负担分析[J]. 实用肿瘤学杂志, 2025, 39(2): 73-79.

WANG Xinyu, CAI Siyu. Analysis of leukemia disease burden in children and adolescents aged 0-19 years in China from 1990 to 2021[J]. Journal of Practical Oncology, 2025, 39(2): 73-79.

参考文献

1 GBD 2021 Diseases and Injuries Collaborators.Global incidence,prevalence,years lived with disability(YLDs),disability-adjusted life-years(DALYs),and healthy life expectancy(HALE)for 371 diseases and injuries in 204 countries and territories and 811 subnational locations,1990-2021:a systematic analysis for the Global Burden of Disease Study 2021[J].Lancet,2024,403(10440):2133-2161.
2 Wu D,Sherwood A,Fromm JR,et al.High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia[J].Sci Transl Med,2012,4(134):134-163.
3 Devarkonda V,Akabane H.Transforming acute myeloid leukemia treatment through next-generation sequencing:a single-center experience[J].Cureus,2023,15(9):e45917.
4 Wu D,Emerson RO,Sherwood A,et al.Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH[J].Clin Cancer Res,2014,20(17):4540-4548.
5 Demidowicz E,Pogorzala M,Lecka M,et al.Outcome of pediatric acute lymphoblastic leukemia:sixty years of progress[J].Anticancer Res,2019,39(9):5203-5207.
6 Ma H,Sun H,Sun X.Survival improvement by decade of patients aged 0-14 years with acute lymphoblastic leukemia:a SEER analysis[J].Sci Rep,2014,4:4227.
7 Bertuccio P,Bosetti C,Malvezzi M,et al.Trends in mortality from leukemia in Europe:an update to 2009 and a projection to 2012[J].Int J Cancer,2013,132(2):427-436.
8 Newman MJ,Benani DJ.A review of blinatumomab,a novel immunotherapy[J].J Oncol Pharm Pract,2016,22(4):639-645.
9 Tlacuilo-Parra A,Garibaldi-Covarrubias R,Romo-Rubio H,et al.Geographical distribution and cluster detection of childhood leukemia in the metropolitan area of guadalajara,Mexico[J].Rev Invest Clin,2017,69(3):159-165.
10 Rodriguez-Abreu D,Bordoni A,Zucca E.Epidemiology of hematological malignancies[J].Ann Oncol,2007,18(Suppl 1):i3-i8.
11 Inaba H,Greaves M,Mullighan CG.Acute lymphoblastic leukaemia[J].Lancet,2013,381(9881):1943-1955.
12 Williams LA,Richardson M,Marcotte EL,et al.Sex ratio among childhood cancers by single year of age[J].Pediatr Blood Cancer,2019,66(6):e27620.
13 Demanelis K,Sriplung H,Meza R,et al.Differences in childhood leukemia incidence and survival between Southern Thailand and the United States:a population-based analysis[J].Pediatr Blood Cancer,2015,62(10):1790-1798.
14 Metayer C,Milne E,Clavel J,et al.The childhood leukemia international consortium[J].Cancer Epidemiol,2013,37(3):336-347.
15 Holmes L,Hossain J,Desvignes-Kendrick M,et al.Sex variability in pediatric leukemia survival:large cohort evidence[J].ISRN Oncol,2012,2012:439070.
16 Keykhaei M,Masinaei M,Mohammadi E,et al.A global,regional,and national survey on burden and Quality of Care Index(QCI)of hematologic malignancies;global burden of disease systematic analysis 1990-2017[J].Exp Hematol Oncol,2021,10(1):11.
17 Whitehead TP,Metayer C,Wiemels JL,et al.Childhood leukemia and primary prevention[J].Curr Probl Pediatr Adolesc Health Care,2016,46(10):317-352.
18 Ren HM,Liao MQ,Tan SX,et al.Global,regional,and national burden of cancer in children younger than 5 years,1990-2019:analysis of the global burden of disease study 2019[J].Front Public Health,2022,10:910641.
19 Nematollahi P,Arabi S,Mansourian M,et al.Environmental risk factors for pediatric acute leukemia:methodology and early findings[J].Int J Prev Med,2023,14(1):103.
20 Wu Y,Deng Y,Wei B,et al.Global,regional,and national childhood cancer burden,1990-2019:An analysis based on the Global Burden of Disease Study 2019[J].J Adv Res,2022,40:233-247.
21 Metayer C,Petridou E,Arangure JM,et al.Parental tobacco smoking and acute myeloid leukemia:the childhood leukemia international consortium[J].Am J Epidemiol,2016,184(4):261-273.
22 Keramatinia A,Mohseny M,Davoudi Monfared E,et al.Parametric models for survival analysis of childhood cancer patients' data[J].Int J Cancer Manag,2022,15(8).
23 Zhan C,Wu Z,Yang L,et al.Disparities in economic burden for children with leukemia insured by resident basic medical insurance:evidence from real-world data 2015-2019 in Guangdong,China[J].BMC Health Serv Res,2022,22(1):229.
24 Johnston DL,Alonzo TA,Gerbing RB,et al.The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival:a Children's Oncology Group study[J].Pediatr Blood Cancer,2010,55(3):414-420.

[1]	文小焱, 陈俐. 2010年和2020年四川省30岁及以上人群恶性肿瘤疾病负担比较分析[J]. 实用肿瘤学杂志, 2025, 39(1): 1-6.
[2]	郑高健, 姚潇妮, 吴忠泽, 贡新宇, 陈王洋, 庞军委. 归因于酒精暴露所致的中国恶性肿瘤死亡和DALY[J]. 实用肿瘤学杂志, 2024, 38(5): 295-299.
[3]	武春龙, 孙伟玲. 中国消化道肿瘤发病与死亡的年龄-时期-队列模型分析[J]. 实用肿瘤学杂志, 2023, 37(6): 459-465.
[4]	王利, 王科进. 骨髓微环境在白血病发病机制中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(6): 524-528.
[5]	张馨, 吴羡美, 李虹, 刘晓舟, 孔德文, 陈琢. 1990—2019年中国女性人群归因于代谢危险因素的乳腺癌疾病负担[J]. 实用肿瘤学杂志, 2023, 37(2): 107-111.
[6]	周孟孟, 徐文超, 俞浩. 1990—2019年江苏省男性前列腺癌疾病负担分析[J]. 实用肿瘤学杂志, 2023, 37(1): 1-5.
[7]	陆小琴, 雷娇娇, 刘雨欣, 赵华清. lncRNA XIST通过miR-375-Notch1轴调控急性T淋巴细胞白血病细胞增殖、侵袭的实验研究[J]. 实用肿瘤学杂志, 2022, 36(5): 404-410.
[8]	王榆平, 思美丽, 孙小霞, 郭玉琳. HPIP在子宫内膜癌中高表达及其在生存预后分析中的意义[J]. 实用肿瘤学杂志, 2022, 36(1): 44-48.
[9]	邬丽婷, 李大兵, 邓小霞, 李柏松. 2013—2020年重庆市北碚区胃癌疾病负担变化趋势及预测[J]. 实用肿瘤学杂志, 2021, 35(6): 495-499.
[10]	朱志超, 白煜, 卢绪章, 孙, 晓, 何流漾, 戚春建. PARP抑制剂olaparib对急性髓系白血病细胞HL-60抑制作用研究[J]. 实用肿瘤学杂志, 2019, 33(6): 481-485.
[11]	袁桂霞, 李岩, 冯婉琪, 夏小娟, 李旭. 抑癌基因DKK2抑制儿童肾母细胞瘤细胞增殖的机制研究[J]. 实用肿瘤学杂志, 2019, 33(1): 14-20.
[12]	付晓英, 李光, 杨彩霞. 骨髓中CDKN1C阳性表达在MDS和AML患者中检测的临床意义[J]. 实用肿瘤学杂志, 2018, 32(2): 112-116.
[13]	李毅鹏, 张鑫宇, 吕涵柠, 孙立春. MLLT6在白血病中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(2): 135-139.
[14]	王艺潼综述, 徐雯审校. 急性早幼粒细胞白血病小鼠动物模型建立的研究现状[J]. 实用肿瘤学杂志, 2017, 31(5): 454-457.
[15]	程卫,赵华. 重组人促甲状腺激素辅助¹³¹I在儿童和青少年分化型甲状腺癌的临床研究[J]. 实用肿瘤学杂志, 2016, 30(4): 309-313.

1990—2021年中国0~19岁儿童和青少年白血病疾病负担分析

Analysis of leukemia disease burden in children and adolescents aged 0-19 years in China from 1990 to 2021

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价